PAVmed Inc. [NASDAQ: PAVM] plunged by -$0.07 during the normal trading session on Friday and reaching a high of $6.31 during the day while it closed the day at $6.19. The company report on June 14, 2021 that Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of Directors. Mr. Baxter will serve as Chair of the Company’s Nomination Committee and as a member of its Audit Committee.
“I am very pleased to welcome Tim Baxter to PAVmed’s Board of Directors,” said Lishan Aklog M.D., PAVmed’s Chairman and Chief Executive Officer. “Mr. Baxter is among the most accomplished and respected executives in the technology industry. His long and distinguished career as a senior global executive at AT&T, Sony and, most recently, at Samsung Electronics, where he was President and CEO, have kept him at the frontlines of technological innovation for over three decades. He shares our passion for leveraging technology in the service of society and has championed the same culture of trust and shared success we have built at PAVmed.”.
PAVmed Inc. stock has also loss -7.75% of its value over the past 7 days. However, PAVM stock has inclined by 18.81% in the 3 months of the year. Over the past six months meanwhile, it has gained 191.98% and gained 191.98% year-on date.
The market cap for PAVM stock reached $524.97 million, with 73.95 million shares outstanding and 73.40 million shares in the current float. Compared to the average trading volume of 2.72M shares, PAVM reached a trading volume of 842916 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PAVmed Inc. [PAVM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PAVM shares is $8.63 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PAVM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for PAVmed Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 30, 2021. While these analysts kept the previous recommendation, Ascendiant Capital Markets raised their target price to Buy. The new note on the price target was released on November 05, 2020, representing the official price target for PAVmed Inc. stock. Previously, the target price had yet another raise to $5, while Maxim Group analysts kept a Buy rating on PAVM stock.
The Average True Range (ATR) for PAVmed Inc. is set at 0.37 The Price to Book ratio for the last quarter was 9.67, with the Price to Cash per share for the same quarter was set at 0.57.
PAVM stock trade performance evaluation
PAVmed Inc. [PAVM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.75. With this latest performance, PAVM shares gained by 10.14% in over the last four-week period, additionally plugging by 191.98% over the last 6 months – not to mention a rise of 201.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PAVM stock in for the last two-week period is set at 54.07, with the RSI for the last a single of trading hit 47.73, and the three-weeks RSI is set at 56.48 for PAVmed Inc. [PAVM]. The present Moving Average for the last 50 days of trading for this stock 5.33, while it was recorded at 6.36 for the last single week of trading, and 3.43 for the last 200 days.
PAVmed Inc. [PAVM]: An insightful look at the core fundamentals
Return on Total Capital for PAVM is now -259.63, given the latest momentum, and Return on Invested Capital for the company is -582.82. When it comes to the capital structure of this company, PAVmed Inc. [PAVM] has a Total Debt to Total Equity ratio set at 789.03. Additionally, PAVM Total Debt to Total Capital is recorded at 88.75, with Total Debt to Total Assets ending up at 75.64.
Reflecting on the efficiency of the workforce at the company, PAVmed Inc. [PAVM] managed to generate an average of -$1,371,040 per employee.PAVmed Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.20 and a Current Ratio set at 15.20.
PAVmed Inc. [PAVM]: Insider Ownership positions
There are presently around $112 million, or 21.70% of PAVM stock, in the hands of institutional investors. The top three institutional holders of PAVM stocks are: BLACKROCK INC. with ownership of 4,354,014, which is approximately 135.578% of the company’s market cap and around 2.60% of the total institutional ownership; VANGUARD GROUP INC, holding 3,462,716 shares of the stock with an approximate value of $21.43 million in PAVM stocks shares; and FMR LLC, currently with $8.67 million in PAVM stock with ownership of nearly New of the company’s market capitalization.
Positions in PAVmed Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 71 institutional holders increased their position in PAVmed Inc. [NASDAQ:PAVM] by around 9,970,293 shares. Additionally, 19 investors decreased positions by around 768,845 shares, while 10 investors held positions by with 7,390,283 shares. The mentioned changes placed institutional holdings at 18,129,421 shares, according to the latest SEC report filing. PAVM stock had 35 new institutional investments in for a total of 4,374,717 shares, while 9 institutional investors sold positions of 209,378 shares during the same period.